Phase II trial evaluates efficacy and safety of radiotherapy in prostate cancer patients, suggesting it can maintain quality of life.
Highlights A phase II trial evaluated 54 Gy in 18 fractions after radical prostatectomy. Moderately hypofractionated radiotherapy showed acceptable acute toxicity. Acute gastrointestinal toxicity was mostly grade 2 and transient. Three-year biochemical recurrence-free survival was 66%. Quality of life was largely maintained after treatment.
No takes yet. Share an insight, caveat, or question.
Sawayanagi et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: